Agios Pharmaceuticals (0HB0) Stock Overview
A biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
0HB0 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Agios Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$28.60 |
| 52 Week High | US$45.81 |
| 52 Week Low | US$22.40 |
| Beta | 0.89 |
| 1 Month Change | 8.95% |
| 3 Month Change | -32.29% |
| 1 Year Change | -13.41% |
| 3 Year Change | -6.94% |
| 5 Year Change | -36.49% |
| Change since IPO | -64.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0HB0 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0.9% | 2.0% | 1.3% |
| 1Y | -13.4% | 29.4% | 22.7% |
Return vs Industry: 0HB0 underperformed the UK Biotechs industry which returned 29.4% over the past year.
Return vs Market: 0HB0 underperformed the UK Market which returned 22.7% over the past year.
Price Volatility
| 0HB0 volatility | |
|---|---|
| 0HB0 Average Weekly Movement | 16.1% |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: 0HB0's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0HB0's weekly volatility has increased from 10% to 16% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 487 | Brian Goff | www.agios.com |
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia.
Agios Pharmaceuticals, Inc. Fundamentals Summary
| 0HB0 fundamental statistics | |
|---|---|
| Market cap | US$1.68b |
| Earnings (TTM) | -US$401.26m |
| Revenue (TTM) | US$44.79m |
Is 0HB0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0HB0 income statement (TTM) | |
|---|---|
| Revenue | US$44.79m |
| Cost of Revenue | US$340.02m |
| Gross Profit | -US$295.22m |
| Other Expenses | US$106.04m |
| Earnings | -US$401.26m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.88 |
| Gross Margin | -659.11% |
| Net Profit Margin | -895.86% |
| Debt/Equity Ratio | 0% |
How did 0HB0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/15 19:34 |
| End of Day Share Price | 2026/01/15 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Agios Pharmaceuticals, Inc. is covered by 31 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| George Farmer | BMO Capital Markets Equity Research |
| Alec Stranahan | BofA Global Research |